Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Rivaroxaban (Xarelto) and Apixaban (Eliquis) for the Prevention of Endothermal Heat-Induced Thrombosis (EHIT) and Deep Vein Thrombosis After Great Saphenous Vein Endovenous Laser Ablation

NCT07699796 is registered in ClinicalTrials.gov with Heart, Artery, and Vein Center of Fresno as lead sponsor.

NCT NCT07699796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07699796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Rivaroxaban (Xarelto) and Apixaban (Eliquis) for the Prevention of Endothermal Heat-Induced Thrombosis (EHIT) and Deep Vein Thrombosis After Great Saphenous Vein Endovenous Laser Ablation
Lead sponsor
Heart, Artery, and Vein Center of Fresno
Phase
Phase 4
Overall status
Completed
Start date
March 6, 2018
Completion date
June 15, 2021
Enrollment
564 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

varicose veins leg, venous insufficiency (chronic)(peripheral), venous thrombosis, venous thrombosis deep (limbs)